Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Assessing risk of bias in randomized controlled trials of methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)

Full text
Author(s):
Rodrigues-Tartari, Raissa [1] ; Swardfager, Walter [2, 3, 4] ; Salum, Giovanni A. [5] ; Rohde, Luis A. [5] ; Cogo-Moreira, Hugo [1]
Total Authors: 5
Affiliation:
[1] Univ Fed Sao Paulo, Dept Psychiat, Rua Borges Lagoa 570, First Floor, BR-04038000 Sao Paulo - Brazil
[2] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON - Canada
[3] Sunnybrook Res Inst, Hurvitz Brain Sci Program, Toronto, ON - Canada
[4] Toronto Rehabil Inst, Univ Hlth Network, Toronto, ON - Canada
[5] Univ Fed Rio Grande do Sul, Dept Psychiat, Porto Alegre, RS - Brazil
Total Affiliations: 5
Document type: Journal article
Source: INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH; v. 27, n. 1 MAR 2018.
Web of Science Citations: 5
Abstract

To test how reliable the tool recommend by Cochrane Collaboration for assessing risk of bias systematic reviews of randomized clinical trials is in the context of methylphenidate for children and adolescents with attention deficit hyperactivity disorder. Confirmatory factor analysis was used to evaluate a unidimensional model for the 7 indicators, applied to 184 Randomized Clinical Trial (RCTs) within a 2015 Cochrane systematic review titled Methylphenidate for children and adolescents with attention deficit hyperactivity disorder. A unidimensional model resulted in excellent adequacy indices, but only 2 indicators had very high factor loadings and low measurement errors. In terms of content, the 7 indicators showed poor reliability (=0.642); however, the set of indicators was precise in evaluating studies with a high amount of bias risk. The Cochrane model of risk of bias as it is, exhibited good fit indices but the majority of the items were not reliable to adequately capture risk of bias in the context of clinical trials of methylphenidate for ADHD. (AU)

FAPESP's process: 16/08208-8 - Evaluating the risk of bias in randomized clinical trials of methylphenidate in attention deficit/hyperactivity disorder: application of confirmatory factor analysis
Grantee:Raissa Rodrigues Tartari
Support Opportunities: Scholarships in Brazil - Scientific Initiation